These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24120777)

  • 1. Re: The burden of urinary incontinence and urinary bother among elderly prostate cancer survivors.
    Taneja SS
    J Urol; 2013 Nov; 190(5):1763-4. PubMed ID: 24120777
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: The burden of urinary incontinence and urinary bother among elderly prostate cancer survivors.
    Griebling TL
    J Urol; 2014 Apr; 191(4):1056. PubMed ID: 24703136
    [No Abstract]   [Full Text] [Related]  

  • 3. The burden of urinary incontinence and urinary bother among elderly prostate cancer survivors.
    Kopp RP; Marshall LM; Wang PY; Bauer DC; Barrett-Connor E; Parsons JK;
    Eur Urol; 2013 Oct; 64(4):672-9. PubMed ID: 23587870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and management of erectile dysfunction after various treatments for prostate cancer.
    Soh J; Kaiho Y; Kikuchi E; Oya M; Yoshioka K; Nakagami Y; Hatano T; Ozu C; Horiguchi Y; Namiki K; Tachibana M; Hisasue S; Tanaka N; Asakawa I
    Int J Urol; 2010 Aug; 17(8):689-97. PubMed ID: 20590940
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry.
    Punnen S; Cowan JE; Chan JM; Carroll PR; Cooperberg MR
    Eur Urol; 2015 Oct; 68(4):600-8. PubMed ID: 25242555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locally advanced prostate cancer: effective treatments, but many adverse effects.
    Prescrire Int; 2013 Jan; 22(134):18-20, 22-3. PubMed ID: 23367679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate Cancer Therapeutics and Their Complications: A Primer for the Primary Care Provider.
    Brownlee Z; De Souza A; Koffer PP; DiPetrillo TA; Mega AE
    R I Med J (2013); 2020 Apr; 103(3):41-45. PubMed ID: 32236161
    [No Abstract]   [Full Text] [Related]  

  • 8. [Quality of life of patients with locally-advanced prostate cancer as a criterium of therapeutic effectiveness].
    Kaprin AD; Kostin AA; Tsybul'skiĭ AD
    Vopr Onkol; 2009; 55(3):285-90. PubMed ID: 19670727
    [No Abstract]   [Full Text] [Related]  

  • 9. How to preserve potency and continence in localized prostate cancer.
    Breda G; Celia A
    BJU Int; 2007 Jul; 100 Suppl 2():29-31. PubMed ID: 17594355
    [No Abstract]   [Full Text] [Related]  

  • 10. [Toxicity of multimodal regimens in prostate cancer].
    Hennequin C
    Prog Urol; 2019 Jun; 29 Suppl 1():S35-S41. PubMed ID: 31307629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychological resilience aspects that mediate the depressive effects of urinary incontinence in prostate cancer survivors 10 years after treatment with radiation and hormone ablation.
    Sharpley CF; Bitsika V; Christie DRH; Bradford R; Steigler A; Denham JW
    J Psychosoc Oncol; 2017; 35(4):438-450. PubMed ID: 28318448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-cancer-associated hypercoagulability: do we need to worry about androgen deprivation?
    Saylor PJ; Fogerty AE
    Lancet Oncol; 2010 May; 11(5):406-7. PubMed ID: 20395175
    [No Abstract]   [Full Text] [Related]  

  • 13. Androgen deprivation therapy for localized and nonmetastatic prostate cancer: too much of a good thing?
    Konijeti R; Kibel AS
    Eur Urol; 2012 Jun; 61(6):1129-30; discussion 1131. PubMed ID: 22445550
    [No Abstract]   [Full Text] [Related]  

  • 14. New trial data do not end the PSA screening debate.
    Vastag B
    J Natl Cancer Inst; 2009 Jun; 101(12):844-5. PubMed ID: 19509364
    [No Abstract]   [Full Text] [Related]  

  • 15. Measuring self-reported sexual function in men with prostate cancer.
    Brucker PS; Cella D
    Urology; 2003 Oct; 62(4):596-606. PubMed ID: 14550425
    [No Abstract]   [Full Text] [Related]  

  • 16. Urinary Bother as a Predictor of Postsurgical Changes in Urinary Function After Robotic Radical Prostatectomy.
    Murphy G; Haddock P; Doak H; Jackson M; Dorin R; Meraney A; Kesler S; Staff I; Wagner JR
    Urology; 2015 Oct; 86(4):817-23. PubMed ID: 26166672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
    Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
    Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Competing risks for patients with localized prostate cancer.
    Seidenfeld J; Samson DJ; Albertsen PC
    J Natl Cancer Inst; 2007 Oct; 99(20):1498-9. PubMed ID: 17925533
    [No Abstract]   [Full Text] [Related]  

  • 19. Lower urinary tract symptoms of prostate cancer patients undergoing treatments over eight-month follow-up.
    Li HC; Chen KM; Lin YH; Chen TB
    J Clin Nurs; 2015 Aug; 24(15-16):2239-46. PubMed ID: 25950902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bother problems in prostate cancer patients after curative treatment.
    Stensvold A; Dahl AA; Brennhovd B; Småstuen MC; Fosså SD; Lilleby W; Steinsvik A; Axcrona K; Smeland S
    Urol Oncol; 2013 Oct; 31(7):1067-78. PubMed ID: 22341412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.